Abstract 2076P
Background
Hand foot syndrome is a distinct side effect associated with capecitabine. Celecoxib, a cyclooxygenase (COX 2) inhibitor is the only drug effective in randomized trials. However, its use in clinics has declined due to concerns regarding cardiac safety. In our trial, we describe the use of topical diclofenac for prevention of HFS in patients receiving capecitabine monotherapy.
Methods
The D torch trial randomized 264 patients with breast or GI cancers receiving capecitabine to apply either 1% topical diclofenac or placebo gel. Stratified permuted variable size block randomization was done using a computer-generated random numbers sequence. The primary objective was to compare the incidence of grade 2 or higher HFS in diclofenac and placebo arms. Secondary objectives were incidence of any grade HFS, capecitabine dose reduction due to HFS and adherence with application. Here, we report the results of the monotherapy subgroup.
Results
108 out of 264 patients received capecitabine monotherapy (56 in diclofenac arm and 52 in placebo arm). Baseline characteristics were well matched in both arms. The study group’s median age was 47 years (IQR 39.5-57.5). Majority were females (n=101, 93.5%). 67 patients (62%) had an ECOG performance status of 0-1, while the rest were PS 2. 95 patients (87.9%) had carcinoma breast and the remaining 13 patients had various gastrointestinal cancers. 63 patients (58.9%) and 41 patients (38.3%) had stage 3 and 4 disease respectively, whereas only 3 patients (2.8%) had stage 2 cancer. Overall, 12 patients developed grade 2 or higher hand foot syndrome, of which 2 were in diclofenac group and 10 were in placebo group (3.6% vs 19.2%, p=0.01). Any grade HFS was seen in 3 patients (5.4%) in diclofenac arm and 12 patients (23%) in placebo arm (p=0.008). Dose reductions of capecitabine were less frequent in the diclofenac arm compared to placebo (3.6% vs 19.2% p=0.01). Adherence to topical treatment was more in the diclofenac group compared to placebo (93.2% vs 82.2%, p=0.04).
Conclusions
Topical diclofenac gel significantly reduced the incidence of HFS in patients receiving capecitabine monotherapy. Topical diclofenac gel application led to less frequent dose reductions of capecitabine.
Clinical trial identification
CTRI/2021/01/030592 (Clinical Trials Registry of India).
Editorial acknowledgement
Legal entity responsible for the study
The authors.
Funding
Alkem Laboratories.
Disclosure
All authors have declared no conflicts of interest.
Resources from the same session
2096P - Morphine titration with intravenous patient-controlled analgesia for severe cancer pain (Mr.TIPS)
Presenter: Seok Jae Huh
Session: Poster session 06
2097P - Incidence, risk factors (RFs) and management of oral mucositis (OM) in patients (pts) treated with a fluoropyrimidines (FP)-based therapy (tp): A retrospective, monocentric experience
Presenter: Fiorella Manfredi
Session: Poster session 06
2098P - The impact of concomitant use of non-opioid analgesics and immune checkpoint inhibitors on survival in lung cancer patients: A Hong Kong population-based cohort study
Presenter: Zheng-Hao Ye
Session: Poster session 06
2099P - The role of ambulatory blood pressure measurement in TKI-induced arterial hypertension diagnosis
Presenter: Elina Khachaturian
Session: Poster session 06
2100P - An exploratory study of the efficacy and safety of hetrombopag in the treatment of thrombocytopenia induced by concurrent or sequential chemoradiotherapy
Presenter: Jun Wang
Session: Poster session 06
2101P - Bleeding Induced by ANtiCAncer drugs (BIANCA) used breast cancer
Presenter: Nicolas Janus
Session: Poster session 06
2102P - Changes in opioid usage after intrathecal morphine pump implantation in patients with terminal cancer (pilot study)
Presenter: Eun Joo Choi
Session: Poster session 06
2103P - Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 a dithiolethione, for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head & neck (H&N) cancer
Presenter: Daniel Osei-Fofie
Session: Poster session 06
2104P - Prevention of taxane chemotherapy induced nail changes and peripheral neuropathy by application of extremity cooling: A prospective single center study with intrapatient comparison
Presenter: Kristen Johnson
Session: Poster session 06
2105P - Prophylactic role of a postbiotic microbiota-stabilizer on abemaciclib-induced diarrhea in breast cancer patients: A pilot application study
Presenter: Rita De Sanctis
Session: Poster session 06